<DOC>
	<DOCNO>NCT01159808</DOCNO>
	<brief_summary>The purpose study test safety different dose strength INX-08189 healthy adult . The study also look rapidly drug break body ( pharmacokinetics PK ) . The study objective include : - To evaluate safety single ascend oral dos INX-08189 healthy subject - To characterize pharmacokinetic ( PK ) profile single ascend oral dos INX-08189 healthy subject - To assess food effect PK single oral dose INX-08189</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Single Ascending Oral Doses INX-08189 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy men postmenopausal ( absence period 2 year ) surgically sterile , nonpregnant , nonlactating woman use reliable form contraception ( see Inclusion Criteria 9 ) 2 . Age 18 65 year , inclusive 3 . Normal ( clinically significant abnormality ) laboratory test ( chemistry , hematology urinalysis ) 4 . No clinically significant abnormality ECG ( QTcB interval must &lt; 450 m ) 5 . Weight ≥ 50kg Body Mass Index ( BMI ) 19 30 , inclusive 6 . Negative urine drug screen screen Study Day 1 7 . Negative serum βHCG pregnancy test screening Study Day 1 ( woman ) 8 . Hepatitis B surface antigen , hepatitis C antibody , HIV antibody negative 9 . Agreement practice barrier method birth control plus use spermicide throughout study period male female subject ( oral contraceptive permit ) 10 . Able complete study visit 11 . Signed informed consent form ( ICF ) 1 . Any active medical problem subject evaluate and/or treat 2 . Calculated creatinine clearance ( calculate use IDMS traceable equation MDRD value ) &lt; 50 mL/min/1.73 m2 3 . Regular use medication , prescription nonprescription ; medication may take within 1 week prior study dose 4 . Use alcohol within 48 hour prior dose ( subject must also agree use alcohol 96 hour dose ) 5 . Current lactation breastfeed 6 . Major surgery within 30 day prior dose 7 . Receipt investigational drug within 30 day prior dose 8 . Donation blood plasma within 30 day prior dose 9 . Any problem , opinion Investigator , affect safety subject outcome study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Safety Pharmacokinetics</keyword>
</DOC>